var docs;if (!docs) docs =[]; docs["75"]={"7500":"<p><b>Title</b> Prostaglandins (Ophthalmic) / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor the clinical intraocular pressure (IOP)-lowering response to ophthalmic prostaglandins closely in patients who are also using nonsteroidal anti-inflammatory agents (NSAIDs). Both enhanced and diminished IOP-lowering have been reported. Though most studies have focused on ophthalmic NSAIDs, systemic NSAIDs have also been implicated in this interaction, thus caution is warranted with any concurrent NSAID, particularly with any sustained/chronic use.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p><b>Prostaglandins (Ophthalmic) Interacting Members</b> Bimatoprost, Latanoprost, Latanoprostene Bunod, Tafluprost, Travoprost, Unoprostone</p>\n</div> \n<p><b>Discussion</b> The intraocular pressure (IOP)-reducing effects of latanoprost were significantly diminished in both healthy volunteers and glaucomatous subjects during coadministration of ophthalmic NSAIDs, with average IOP increases ranging from 1.1-1.6 mmHg (or approximately 6-14%) compared to non-NSAID controls.<sup>1,2,3</sup><br><br>Conversely, the opposite effect has been reported in other studies in which the IOP-reducing effects of latanoprost, travoprost, and/or bimatoprost were enhanced in both healthy volunteers and glaucomatous subjects during coadministration of ophthalmic NSAIDs. The average enhancement in IOP reduction was 2.6-4.1 mmHg in NSAID recipients as compared to non-NSAID controls.<sup>4,5,6,7</sup> While most studies have examined the IOP effects of ophthalmic NSAIDs, two studies by the same group also found enhanced IOP-lowering effects when oral ketorolac or nimesulide were administered to patients being treated with latanoprost;<sup>4,5</sup> however, in another study oral indomethacin did not significantly alter the IOP-reducing effects of latanoprost.<sup>8</sup><br><br>The mechanism of any NSAID-prostaglandin analog interaction is uncertain but is thought to involve modulation of endogenous prostaglandin concentrations/effects. However, the variable effects reported in clinical studies makes it difficult to fully explain or predict how these drugs may interact with one another. Lack of consistency in trials further limits the conclusions that can be drawn regarding the clinical significance of this data. Sample sizes were roughly similar across the studies, and both enhanced IOP reduction and diminished IOP reduction were reported in both healthy and subjects with glaucoma. Treatment durations and length of co-administration period vary considerably among the studies but do not appear to explain the varied finding. In the studies analyzed here, those which demonstrated diminished IOP lowering effect were typically of longer duration. In two of the three studies by the Costagliola group, which demonstrated enhanced IOP lowering effect during coadministration, IOP was only measured for a 24-hour period following a single dose/application of NSAID,<sup>4,5</sup> whereas IOP was monitored over a period of days to weeks in other studies.<sup>1,2,3,6,7</sup> Variations in type of NSAID and differences in administration are other proposed explanations for the observed discrepancies in effect.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chiba T, Kashiwagi K, Chiba N, et al, “Effect of Non-Steroidal Anti-Inflammatory Ophthalmic Solution on Intraocular Pressure Reduction by Latanoprost in Patients with Primary Open Angle Glaucoma or Ocular Hypertension,” <i>Br J Ophthalmol</i>, 2006, 90(3):314-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16488953\">[PubMed 16488953]</a></p>\n<p>2. Kashiwagi K, Tsukahara S, “Effect of Non-Steroidal Anti-Inflammatory Ophthalmic Solution on Intraocular Pressure Reduction by Latanoprost,” <i>Br J Ophthalmol</i>, 2003, 87(3):297-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598441\">[PubMed 12598441]</a></p>\n<p>3. Sorkhabi R, Alipanahi R, Eftakhari-Milani A, et al, “The Influence of Topical Diclofenac Sodium on the Ocular Hypotensive Effect of Latanoprost in Glaucoma Patients,” <i>J Glaucoma</i>, 2011, 20(4):240-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20577116\">[PubMed 20577116]</a></p>\n<p>4. Costagliola C, Campa C, Perri P, et al, “Topical and Oral Ketorolac Administration Increases the Intraocular Pressure-Lowering Effect of Latanoprost,” <i>Curr Eye Res</i>, 2008, 33(5):477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18568885\">[PubMed 18568885]</a></p>\n<p>5. Costagliola C, Parmeggiani F, Caccavale A, et al, “Nimesulide Oral Administration Increases the Intraocular Pressure-Lowering Effect of Latanoprost in Patients with Primary Open-Angle Glaucoma,” <i>Am J Ophthalmol</i>, 2006, 141(2):379-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16458700\">[PubMed 16458700]</a></p>\n<p>6. Costagliola C, Parmeggiani F, Antinozzi PP, et al, “The Influence of Diclofenac Ophthalmic Solution on the Intraocular Pressure-Lowering Effect of Topical 0.5% Timolol and 0.005% Latanoprost in Primary Open-Angle Glaucoma Patients,” <i>Exp Eye Res</i>, 2005, 81(5):610-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15949795\">[PubMed 15949795]</a></p>\n<p>7. Turan-Vural E, Torun-Acar B, Acar S, “Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues,” <i>Ophthalmologica</i>, 2012, 27(4):205-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22116588\">[PubMed 22116588]</a></p>\n<p>8. Sponsel WE, Paris G, Trigo Y, et al, “Latanoprost and Brimonidine: Therapeutic and Physiologic Assessment Before and After Oral Nonsteroidal Anti-Inflammatory Therapy,” <i>Am J Ophthalmol</i>, 2002, 133(1):11-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11755835\">[PubMed 11755835]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7501":"<p><b>Title</b> Monoamine Oxidase Inhibitors / OxyCODONE</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This combination is listed as contraindicated in Canadian labeling but not US labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> OxyCODONE may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> US labeling for the oxycodone/naltrexone combination product recommends avoiding use during and within 14 days of discontinuation of monoamine oxidase inhibitor treatment. Related warnings are not currently included in labeling for other oxycodone products, but will be added based on a March 2016 FDA Drug Safety Communication. Canadian oxycodone labeling states that use during and within 14 days after monoamine oxidase inhibitor treatment is contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Canadian oxycodone labeling states that use during and within 14 days of stopping monoamine oxidase (MAO) inhibitor treatment is contraindicated, and may result in effects including anxiety, confusion, and respiratory depression.<sup>1,2,3</sup> US labeling for oxycodone/naltrexone also recommends avoiding use during and within 14 days of discontinuation of monoamine oxidase inhibitor treatment.<sup>4</sup> Related warnings are not currently included in US labeling for other oxycodone products, but will be added based on a 2016 FDA Drug Safety Communication regarding the potential for serotonin toxicity/serotonin syndrome with these combinations.<sup>5</sup> Published case reports describe possible serotonin syndrome/toxicity in patients taking selective serotonin reuptake inhibitors and oxycodone.<sup>6,7</sup> The independent serotonergic action of oxycodone has been questioned based on serotonin uptake data,<sup>8</sup> but comprehensive mechanistic investigations have been conducted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Targin (oxycodone/naloxone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; December 2012.</p>\n<p>2. Oxy IR (oxycodone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; June 2012.</p>\n<p>3. Apo-Oxycodone CR (oxycodone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; November 2012.</p>\n<p>4. Troxyca ER (oxycodone/naltrexone) [prescribing information]. New York, NY: Pfizer Inc; August 2016.</p>\n<p>5. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm. Published March 22, 2016. Accessed August 29, 2016.</p>\n<p>6. Walter C, Ball D, Duffy M, Mellor JD. An unusual case of serotonin syndrome with oxycodone and citalopram [published online May 29, 2012]. <i>Case Rep Oncol Med</i>. 2012;2012:261787. doi: 10.1155/2012/261787. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22690346\">[PubMed 22690346]</a></p>\n<p>7. Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. <i>Ann Pharmacother</i>. 2006;40(1):155-157. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368927\">[PubMed 16368927]</a></p>\n<p>8. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>Br J Anaesth</i>. 2005;95(4):434-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7502":"<p><b>Title</b> QuiNINE / Tetracycline (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetracycline (Systemic) may increase the serum concentration of QuiNINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients receiving this combination should be followed closely for evidence of quinine toxicity. It is unclear whether other tetracyclines would interact in a similar manner.</p> \n<p><b>Discussion</b> According to the quinine prescribing information, quinine concentrations were approximately 2-fold higher when quinine (600 mg every 8 hours) was used together with tetracycline (250 mg every 8 hours) in patients with malaria.<sup>1</sup> The quinine minimum plasma concentration (Cmin) was below the falciparum MIC (10 mcg/mL) in all 8 subjects who received quinine alone but was above the MIC in all 8 subjects who received quinine plus tetracycline.<sup>2</sup><br><br>The mechanism for this interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinine). Philadelphia, PA: AR Scientific, Inc., April 2013.</p>\n<p>2. Karbwang J, Molunto P, Bunnag D, et al, “Plasma Quinine Levels in Patients with Falciparum Malaria when Given Alone or in Combination with Tetracycline with or without Primaquine,” <i>Southeast Asian J Trop Med Public Health</i>, 1991, 22(1):72-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1948263\">[PubMed 1948263]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7503":"<p><b>Title</b> Fosphenytoin-Phenytoin / Methotrexate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methotrexate may decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically, fosphenytoin-phenytoin may displace methotrexate from serum proteins, increasing the concentration of free, unbound drug. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin concentrations/effects during methotrexate treatment and a return toward baseline phenytoin concentrations/effects over days to weeks following methotrexate treatment. Adjust phenytoin dose as necessary to maintain concentrations in the desired range. Additionally, the manufacturer of methotrexate suggests increased monitoring for methotrexate toxicities if combined with phenytoin. Lower (eg, antirheumatic) doses of methotrexate likely carry less risk than higher (eg, antineoplastic) doses.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> A 46-year-old man who had been receiving long-term anticonvulsant treatment with phenytoin 350 mg daily and phenobarbital 100 mg daily for seizure activity due to brain metastases from lung cancer experienced a severe increase in partial seizure activity and a decrease in phenytoin plasma concentration from 9.4 to 5.6 mcg/mL, both of which were observed 24 hours after the patient received a second cycle of antineoplastic therapy with a combination regimen of vinblastine, methotrexate and carmustine.<sup>1</sup> Phenytoin plasma concentrations remained low throughout the patient's hospital stay; a phenytoin concentration two weeks following discharge was 9 mcg/mL. A similar trend occurred during the patient's third cycle of antineoplastic therapy. Decreases in serum phenytoin concentrations have also been reported with other methotrexate containing chemotherapeutic regimens<sup>2,3</sup>, however, what role methotrexate played versus the other medications in each regimen remains unclear. <br><br>The potential mechanism of this interaction between phenytoin and methotrexate is unclear. Impaired absorption of phenytoin due to damaged intestinal mucosa from methotrexate has been proposed<sup>1</sup> and has been a suggested mechanism contributing to decreased phenytoin concentrations associated with other chemotherapeutic agents.<sup>4,5,6</sup> Increased phenytoin clearance has also been proposed, but evidence to support the role of methotrexate in this mechanism is limited.<sup>2</sup> Product labeling for methotrexate also warns that increased toxicities may occur if combined with drugs that displace methotrexate from serum proteins, such as phenytoin.<sup>7</sup> However, no reports have been published that document increased methotrexate toxicities when combined with phenytoin. <br><br>While more data are essential to further understand this interaction, close monitoring of phenytoin concentrations along with signs of methotrexate toxicity seems prudent during concomitant use, and doses should be adjusted as necessary.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bollini P, Riva R, Albani F, et al. Decreased phenytoin level during antineoplastic therapy: a case report. <i>Epilepsia</i>. 1983;24(1):75-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6822234\">[PubMed 6822234]</a></p>\n<p>2. Jarosinski PF, Moscow JA, Alexander MS, Lesko LJ, Balis FM, Poplack DG. Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia. <i>J Pediatr</i>. 1988;112(6):996-999. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3163735\">[PubMed 3163735]</a></p>\n<p>3. Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. <i>Ann Pharmacother</i>. 1996;30(5):520-526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8740335\">[PubMed 8740335]</a></p>\n<p>4. Fincham RW, Schottelius DD. Decreased phenytoin levels in antineoplastic therapy. <i>Ther Drug Monit</i>. 1979;1(2):277-283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=555575\">[PubMed 555575]</a></p>\n<p>5. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. <i>Am J Med</i>. 1989;87(5):505-510. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2683764\">[PubMed 2683764]</a></p>\n<p>6. Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin. <i>Ther Drug Monit</i>. 1984;6(3):302-305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6209833\">[PubMed 6209833]</a></p>\n<p>7. Methotrexate [prescribing information]. Lake Forest, IL: Hospira Inc; October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7504":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor phenytoin-treated patients closely for altered response to neuromuscular-blocking agents. Acute phenytoin (i.e., within 7-14 days of initiation) is expected to enhance neuromuscular-blocking agent effect, while longer-term phenytoin (i.e., after 7-14 days) is expected to diminish neuromuscular-blocking agent response. Patients receiving chronic phenytoin therapy should be monitored for more rapid recovery from neuromuscular blockade than expected, and neuromuscular blocker infusion rate requirements may be higher.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Several studies report both increased and decreased neuromuscular blockade in patients receiving concurrent phenytoin. Acute/short-term use of phenytoin (less than 7-14 days) has been shown to enhance the effect of neuromuscular-blocking agents in several patients.<sup>1,2,3</sup> Other reports describe relative resistance to neuromuscular blockade, decreased neuromuscular-blocking intensity, and decreased neuromuscular-blocking agent duration of action in patients who had received chronic phenytoin therapy.<sup>3,4,5,6,7,8,9,10,11,12,13,14</sup><br><br>The mechanism(s) by which acute phenytoin enhances neuromuscular blockade is not certain, though many mechanisms have been proposed, including: postjunctional blockade, prejunctional blockade, decreased acetylcholine synthesis, and phenytoin-mediated displacement of neuromuscular blocker protein binding.<sup>1,4</sup><br><br>The mechanism(s) by which chronic phenytoin interferes with neuromuscular blockade is also unclear, with enhanced neuromuscular-blocking agent clearance (via induction of metabolism) and receptor upregulation (due to increased number of extra-junctional receptors) among the proposed mechanisms for this effect.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gray HS, Slater RM, Pollard BJ, “The Effect of Acutely Administered Phenytoin on Vecuronium-Induced Neuromuscular Blockade,” <i>Anaesthesia</i>, 1989, 44(5):379-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2568098\">[PubMed 2568098]</a></p>\n<p>2. Baumgardner JE, Bagshaw R, “Acute Versus Chronic Phenytoin Therapy and Neuromuscular Blockade,” <i>Anaesthesia</i>, 1990, 45(6):493-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1974393\">[PubMed 1974393]</a></p>\n<p>3. Kim JU, Lee YK, Lee YM, et al, “The Effect of Phenytoin on Rocuronium-Induced Neuromuscular Block in the Rat Phrenic Nerve-Hemidiaphragm Preparation,” <i>J Neurosurg Anesthesiol</i>, 2005, 17(3):149-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16037736\">[PubMed 16037736]</a></p>\n<p>4. Wright PM, McCarthy G, Szenohradszky J, et al, “Influence of Chronic Phenytoin Administration on the Pharmacokinetics and Pharmacodynamics of Vecuronium,” <i>Anesthesiology</i>, 2004, 100(3):626-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15108978\">[PubMed 15108978]</a></p>\n<p>5. Fernandez-Candil J, Gambus PL, et al, “Pharmacokinetic-Pharmacodynamic Modeling of the Influence of Chronic Phenytoin Therapy on the Rocuronium Bromide Response in Patients Undergoing Brain Surgery,” <i>Eur J Clin Pharmacol</i>, 2008, 64(8):795-806. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18521585\">[PubMed 18521585]</a></p>\n<p>6. Spacek A, Nickl S, Neiger FX, et al, “Augmentation of the Rocuronium-Induced Neuromuscular Block by the Acutely Administered Phenytoin,” <i>Anesthesiology</i>, 1999, 90(6):1551-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10360851\">[PubMed 10360851]</a></p>\n<p>7. Richard A, Girard F, Girard DC, et al, “Cisatracurium-Induced Neuromuscular Blockade is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients,” <i>Anesth Analg</i>, 2005, 100(2):538-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673889\">[PubMed 15673889]</a></p>\n<p>8. Soriano SG, Sullivan LJ, Venkatakrishnan K, et al, “Pharmacokinetics and Pharmacodynamics of Vecuronium in Children Receiving Phenytoin or Carbamazepine for Chronic Anticonvulsant Therapy,” <i>Br J Anaesth</i>, 2001, 86(2):223-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11573664\">[PubMed 11573664]</a></p>\n<p>9. Koenig MH, Edwards LT, “Cisatracurium-Induced Neuromuscular Blockade in Anticonvulsant Treated Neurosurgical Patients,” <i>J Neurosurg Anesthesiol</i>, 2000, 12(4):314-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11147379\">[PubMed 11147379]</a></p>\n<p>10. Platt PR, Thackray NM, “Phenytoin-Induced Resistance to Vecuronium,” <i>Anaesth Intensive Care</i>, 1993, 21(2):185-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8100123\">[PubMed 8100123]</a></p>\n<p>11. Liberman BA, Norman P, Hardy BG, “Pancuronium-Phenytoin Interaction: A Case of Decreased Duration of Neuromuscular Blockade,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1988, 26(8):371-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3220609\">[PubMed 3220609]</a></p>\n<p>12. Kira S, “[Resistance to Vecuronium Induced Muscle Relaxation in a Patient with Mental Retardation Receiving Phenytoin for Chronic Anticonvulsant Therapy],” <i>Masui</i>, 2011, 60(1):80-3. (article in Japanese) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21348254\">[PubMed 21348254]</a></p>\n<p>13. Ornstein E, Matteo RS, Schwartz AE, et al, “The Effect of Phenytoin on the Magnitude and Duration of Neuromuscular Block Following Atracurium or Vecuronium,” <i>Anesthesiology</i>, 1987, 67(2):191-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2886081\">[PubMed 2886081]</a></p>\n<p>14. Hernandez-Palazon J, Tortosa JA, Martinez-Lage JF, et al, “Rocuronium-Induced Neuromuscular Blockade is Affected by Chronic Phenytoin Therapy,” <i>J Neurosurg Anesthesiol</i>, 2001, 13(2):79-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11294462\">[PubMed 11294462]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7505":"<p><b>Title</b> Fosphenytoin-Phenytoin / Platinum Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin concentrations/effects during treatment with a platinum derivative and a return toward baseline phenytoin concentrations/effects over days to weeks following platinum derivative treatment. Adjust phenytoin dose as necessary to maintain concentrations in the desired range.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n <p><b>Platinum Derivatives Interacting Members</b> CARBOplatin, CISplatin, Oxaliplatin</p>\n</div> \n<p><b>Discussion</b> Case reports describe decreased phenytoin concentrations during cisplatin or carboplatin chemotherapy.<sup>1,2,3,4</sup> One of these cases describes the course of a 24-year-old pregnant woman with a malignant germ cell tumor who was treated with cisplatin, vinblastine, and bleomycin chemotherapy (CVB) and prochlorperazine and secobarbital for nausea and vomiting who experienced a seizure two days after completion of her first chemotherapy cycle.<sup>1</sup> The patient received a phenytoin loading dose of 16 mg/kg, began phenytoin 200 mg twice/day, and was admitted for her next CVB cycle; at the time phenytoin serum concentration was 9.6 mcg/mL so the phenytoin dose was increased to 300 mg in the morning and 200 mg in the evening. On the day of discharge, after completing the chemotherapy cycle, the patient experienced 2 seizures and was found to have a serum phenytoin concentration of 2 mcg/mL despite continuing phenytoin at the increased dose. The dose was not changed, and the patient was discharged the following day. The patient was admitted 3 weeks later for her next chemotherapy cycle with a phenytoin serum concentration of 11.4 mcg/mL. Under daily monitoring of phenytoin concentrations, with supplemental dosing to maintain therapeutic concentrations, the phenytoin concentration was maintained at 8.1 mcg/mL or above for the duration of the hospital stay and no further seizure activity was reported. Mean absorption of phenytoin was estimated to have decreased to around 32% during this cycle (normal = greater than 80%);<sup>1</sup> although, vomiting and secobarbital induction of phenytoin metabolism may also have played a role in reducing concentrations. Another case report also describes decreased phenytoin concentrations during carboplatin chemotherapy.<sup>2</sup> A 64-year-old man with recurrent brain metastases was started on dexamethasone 16 mg daily and phenytoin 300 mg daily, producing serum phenytoin concentrations of 8.9-9.4 mcg/mL. Ten days after the start of carboplatin chemotherapy, the patient's seizures recurred, and his phenytoin serum concentration was found to be 4.6 mcg/mL. The phenytoin dose was then increased to 425 mg daily at which point seizures disappeared.<br><br>In a retrospective review, all patients receiving phenytoin during chemotherapy (carmustine + cisplatin, N=5; and carmustine + cranial radiation, N=5) as part of an autologous bone marrow transplantation regimen required dose increases to maintain therapeutic phenytoin concentrations around the time of chemotherapy (mean 134% increase in dose, range 50-300%).<sup>4</sup> Dose requirements neared pre-chemotherapy levels by the time of discharge, approximately 3-4 weeks after chemotherapy started. In a retrospective review of adult patients receiving chemotherapy with cisplatin and carmustine for astrocytomas, with concomitant dexamethasone, metoclopramide, and diphenhydramine, 10/10 patients followed for 3 or more chemotherapy cycles required increased phenytoin doses to maintain therapeutic serum concentrations (mean 41% increase in dose, range 20-100%; cycles accompanied by vomiting excluded).<sup>5</sup> Fourteen of 19 patients studied for any number of cycles required dose increases. No changes in phenytoin doses were required for patients receiving carmustine alone.<br><br>The potential mechanism of interaction between phenytoin and cisplatin is unknown. Authors of two case reports suggest phenytoin malabsorption as a possible mechanism,<sup>1,3</sup> but this mechanism has not been further explored. In studies to date, concentrations of other oral drugs have not been affected to the same extent as phenytoin.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sylvester RK, Lewis FB, Caldwell KC, et al, “Impaired Phenytoin Bioavailability Secondary to Cisplatinum, Vinblastine, and Bleomycin,” <i>Ther Drug Monit</i>, 1984, 6(3):302-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6209833\">[PubMed 6209833]</a></p>\n<p>2. Dofferhoff AS, Berendsen HH, vd Naalt J, et al, “Decreased Phenytoin Level after Carboplatin Treatment,” <i>Am J Med</i>, 1990, 89(2):247-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2200266\">[PubMed 2200266]</a></p>\n<p>3. Fincham RW and Schottelius DD, “Decreased Phenytoin Levels in Antineoplastic Therapy,” <i>Ther Drug Monit</i>, 1979, 1(2):277-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=555575\">[PubMed 555575]</a></p>\n<p>4. Ghosh C, Lazarus HM, Hewlett JS, et al, “Fluctuation of Serum Phenytoin Concentrations during Autologous Bone Marrow Transplant for Primary Central Nervous System Tumors,” <i>J Neurooncol</i>, 1992, 12(1):25-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1311752\">[PubMed 1311752]</a></p>\n<p>5. Grossman SA, Sheidler VR and Gilbert MR, “Decreased Phenytoin Levels in Patients Receiving Chemotherapy,” <i>Am J Med</i>, 1989, 87(5):505-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2683764\">[PubMed 2683764]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7506":"<p><b>Title</b> Phenytoin / Bleomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bleomycin may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin concentrations/effects during bleomycin treatment and a return toward baseline phenytoin concentrations/effects over days following bleomycin treatment. Adjust phenytoin dose as necessary to maintain concentrations in the desired range.</p> \n<p><b>Discussion</b> Case reports describe decreased phenytoin concentrations during bleomycin chemotherapy.<sup>1,2</sup> One of these cases describes the course of a 24-year-old pregnant woman with a malignant germ cell tumor who was treated with cisplatin, vinblastine, and bleomycin chemotherapy (CVB) and prochlorperazine and secobarbital for nausea and vomiting who experienced a seizure two days after completion of her first chemotherapy cycle.<sup>1</sup> The patient received a phenytoin loading dose of 16 mg/kg, began phenytoin 200 mg twice/day, and was admitted for her next CVB cycle; at the time phenytoin serum concentration was 9.6 mcg/mL so the phenytoin dose was increased to 300 mg in the morning and 200 mg in the evening. On the day of discharge, after completing the chemotherapy cycle, the patient experienced 2 seizures and was found to have a serum phenytoin concentration of 2 mcg/mL despite continuing phenytoin at the increased dose. The dose was not changed, and the patient was discharged the following day. The patient was admitted 3 weeks later for her next chemotherapy cycle with a phenytoin serum concentration of 11.4 mcg/mL. Under daily monitoring of phenytoin concentrations, with supplemental dosing to maintain therapeutic concentrations, the phenytoin concentration was maintained at 8.1 mcg/mL or above for the duration of the hospital stay and no further seizure activity was reported. Mean absorption of phenytoin was estimated to have decreased to around 32% during this cycle (normal = greater than 80%).<sup>1</sup><br><br>The potential mechanism of this interaction between phenytoin and bleomycin is not well defined; however, authors of two case reports suggest cytotoxic-induced changes in the intestinal mucosa may lead to phenytoin malabsorption.<sup>1,2</sup> Loss of phenytoin due to emesis, secobarbital induction of phenytoin metabolism and increased renal excretion of phenytoin due to cisplatin-induced neprotoxicity may also have played a role in reducing phenytoin concentrations.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sylvester RK, Lewis FB, Caldwell KC, et al, “Impaired Phenytoin Bioavailability Secondary to Cisplatinum, Vinblastine, and Bleomycin,” <i>Ther Drug Monit</i>, 1984, 6(3):302-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6209833\">[PubMed 6209833]</a></p>\n<p>2. Fincham RW and Schottelius DD, “Decreased Phenytoin Levels in Antineoplastic Therapy,” <i>Ther Drug Monit</i>, 1979, 1(2):277-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=555575\">[PubMed 555575]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7507":"<p><b>Title</b> Domperidone / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response to both drugs closely when used together.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The domperidone product monograph notes that caution should be used when using domperidone together with monoamine oxidase (MAO) inhibitors.<sup>1</sup> However, the specific nature of or reason for this caution is unclear, as no further information is provided and no published reports about this purported interaction are available.<br><br>Given the ability of MAOIs to inhibit the metabolism of dopamine and other catecholamines, MAOIs and domperidone (which is a dopamine receptor antagonist) could theoretically interfere with the actions of one another, though no data supporting such an interaction are available. Whether this is basis for the warning or whether the warning is due to some concern for additive toxicities is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Dom-Domperidone (domperidone). Montreal, Quebec, Canada: Dominion Pharmaceutical, May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7508":"<p><b>Title</b> Isometheptene / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Isometheptene. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of isometheptene during or within 2 weeks of any monoamine oxidase inhibitor.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for isometheptene states that coadministraiton within 2 weeks of a monoamine oxidase inhibitor should be avoided, due to the potential for a serious and possibly fatal drug interaction.<sup>1</sup> The exact mechanism of this interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Isometheptene mucate, dichloralphenazone, and acetaminophen. Magnolia, TX: Macoven Pharmaceuticals, LLC, 2/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7509":"<p><b>Title</b> Cimetidine / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AtorvaSTATin may enhance the adverse/toxic effect of Cimetidine. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use cimetidine with caution in patients receiving atorvastatin, due to a theoretical potential for enhanced reductions in endogenous steroid activity.</p> \n<p><b>Discussion</b> Atorvastatin U.S. prescribing information warns that it should be coadministered cautiously with cimetidine due to a theoretical potential for additive effects of the two agents on reducing endogenous steroid activity.<sup>1</sup> Although cimetidine is an inhibitor of both CYP3A4 and the P-glycoprotein transporter, there was no or minimal alteration of atorvastatin exposure in two clinical studies with cimetidine coadministration.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lipitor (atorvastatin). New York, NY: Pfizer, Inc, February 2012.</p>\n<p>2. Stern RH, Gibson DM and Whitfield LR, “Cimetidine Does Not Alter Atorvastatin Pharmacokinetics or LDL-Cholesterol Reduction,” <i>Eur J Clin Pharmacol</i>, 1998, 53(6):475-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9551707\">[PubMed 9551707]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7510":"<p><b>Title</b> Spironolactone / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AtorvaSTATin may enhance the adverse/toxic effect of Spironolactone. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use spironolactone with caution in patients receiving atorvastatin, due to a theoretical potential for enhanced reductions in endogenous steroid activity.</p> \n<p><b>Discussion</b> Atorvastatin U.S. prescribing information warns that it should be coadministered cautiously with spironolactone due to a theoretical potential for additive effects of the two agents on reducing endogenous steroid activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lipitor (atorvastatin). New York, NY: Pfizer, Inc, February 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7511":"<p><b>Title</b> Technetium Tc 99m Tilmanocept / Local Anesthetics</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only expected when mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.</p>\n<div>\n <p><b>Local Anesthetics Interacting Members</b> Articaine, Benoxinate, Bupivacaine, Bupivacaine (Liposomal), Chloroprocaine, Levobupivacaine, Lidocaine (Systemic), Mepivacaine, Prilocaine, Procaine, Ropivacaine, Tetracaine (Systemic)<br><b>Exceptions</b> Benzocaine, Benzydamine, Cocaine (Topical), Dibucaine, Dyclonine, Ethyl Chloride, Hexylresorcinol, Lidocaine (Ophthalmic), Lidocaine (Topical), Pramoxine, Proparacaine, Tetracaine (Ophthalmic), Tetracaine (Topical)</p>\n</div> \n<p><b>Discussion</b> Technetium Tc 99m tilmanocept U.S. prescribing information states that simultaneous injection with local anesthetics may impair lymph node mapping, based on animal data indicating reduced lymphatic flow in the presence of local anesthetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lymphoseek (technetium TC 99m tilmanocept). Dublin, OH: Navidea Biopharmaceuticals, Inc., 2/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7512":"<p><b>Title</b> Methemoglobinemia Associated Agents / Nitric Oxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Age</b>: In infants, avoid concomitant use of nitric oxide in combination with lidocaine/prilocaine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nitric Oxide may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants given nitric oxide.</p>\n<div>\n <p><b>Methemoglobinemia Associated Agents Interacting Members</b> Acetaminophen, Amyl Nitrite, Benzocaine, Celecoxib, Chloroquine, Dapsone (Systemic), Dapsone (Topical), Flutamide, Isosorbide Dinitrate, Isosorbide Mononitrate, Lidocaine (Systemic), Lidocaine (Topical), Mafenide, Metoclopramide, Nicorandil, Nitric Oxide, Nitrofurantoin, Nitroglycerin, Nitroprusside, Phenazopyridine, PHENobarbital, Phenytoin, Prilocaine, Primaquine, Propacetamol, QuiNINE, Sodium Nitrite, SulfADIAZINE, Sulfamethoxazole, SulfaSALAzine, Tetracaine (Topical), Zopiclone</p>\n</div> \n<p><b>Discussion</b> Nitric oxide U.S. prescribing information warns about the potential for development of methemoglobinemia during treatment, and the potential for other nitric oxide donor compounds to enhance this potential.<sup>1</sup> Methemoglobinemia has been described in published case reports of nitric oxide coadministration with other agents associated with methemoglobinemia.<sup>2,3</sup> In general, patients at increased risk of clinically significant methemoglobinemia include very young patients, those with glucose-6-phosphate deficiencies, those with congenital or idiopathic methemoglobinemia, and those receiving multiple drugs associated with development of methemoglobinemia.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Inomax (nitric oxide). Hampton, NJ: INO Therapeutics, 3/2013.</p>\n<p>2. Sinisterra S, Miravet E, Alfonso I, et al, “Methemoglobinemia in an Infant Receiving Nitric Oxide After the Use of Eutectic Mixture of Local Anesthetic,” <i>J Pediatr</i>, 2002, 141(2):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12183731\">[PubMed 12183731]</a></p>\n<p>3. Lopez A, Bernardo B, Lopez-Herce J, et al, “Methaemoglobinaemia Secondary to Treatment With Trimethoprim and Sulphamethoxazole Associated With Inhaled Nitric Oxide,” <i>Acta Paediatr</i>, 1999, 88(8):915-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10503695\">[PubMed 10503695]</a></p>\n<p>4. Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010.</p>\n<p>5. Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7513":"<p><b>Title</b> QUEtiapine / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The Canadian labeling for both atazanavir/cobicistat and nefinavir state that concurrent use with quetiapine is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In patients receiving quetiapine, reduce the quetiapine dose to one sixth of the regular dose following initiation of any strong CYP3A4 inhibitor. Increase the quetiapine dose by 6-fold following discontinuation of the CYP3A4 inhibitor. In patients receiving strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and up-titrate cautiously as needed. The Canadian labeling for both atazanavir/cobicistat and nelfinavir specify that concurrent use with quetiapine is not recommend, but that if the combination is necessary, the quetiapine dose should be reduced.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in quetiapine U.S. prescribing information, coadministraiton of ketoconazole (200 mg daily for 4 days) increased the maximum concentration and AUC of quetiapine (25 mg single dose) by 3.4 and 6.2 fold, respectively.<sup>1,2,3</sup> Additionally, several published case reports describe adverse clinical effects (weight gain, sedation, confusion, respiratory depression) and/or prolonged quetiapine elimination (estimated half-life over 62 hours in a patient following overdose) in patients receiving quetiapine during or proximate to use of strong CYP3A4 inhibitors.<sup>4,5,6,7</sup> A retrospective review of therapeutic drug monitoring data also detected a non-significant 71% greater median quetiapine serum concentration/dose ratio in patients receiving concurrent drugs that interact with CYP3A4, although the exact agents included in this analysis are not defined and the authors state that only 1 patient received a “high affinity” CYP3A4 inhibitor (nefazodone).<sup>8</sup><br><br>The suspected primary mechanism of these interactions is inhibition of CYP3A4 mediated quetiapine metabolism by the coadministered agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2013.</p>\n<p>2. Seroquel XR (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2013.</p>\n<p>3. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. <i>Br J Clin Pharmacol</i>. 2006;61(1):58-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16390352\">[PubMed 16390352]</a></p>\n<p>4. Hantson P, Di Fazio V, Wallemacq P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. <i>Drug Metab Lett</i>. 2010;4(1):7-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20201782\">[PubMed 20201782]</a></p>\n<p>5. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. <i>Pharmacotherapy</i>. 2009;29(11):1386-1391. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19857154\">[PubMed 19857154]</a></p>\n<p>6. Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. <i>Pharmacopsychiatry</i>. 2008;41(6):258-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19067264\">[PubMed 19067264]</a></p>\n<p>7. Worthley DL, Burgess N, Nigro O, Shakib S. Seroquel, Serzone and seizures. <i>Intern Med J</i>. 2004;34(3):134-135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15030464\">[PubMed 15030464]</a></p>\n<p>8. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. <i>Ther Drug Monit</i>. 2004;26(5):486-491. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385830\">[PubMed 15385830]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7514":"<p><b>Title</b> QUEtiapine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit during treatment with a strong CYP3A4 inducer. The quetiapine dose should be reduced to the previous/regular dose within 7-14 days of discontinuation of the CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine*, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin*, Primidone, RifAMPin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in quetiapine U.S. prescribing information, coadministraiton of phenytoin (100 mg 3 times daily) decreased the maximum concentration and AUC of quetiapine (250 mg 3 times daily) by 73% and 81%, respectively.<sup>1,2,3</sup> Similarly, in a study of 18 psychiatric patients, carbamazepine (200 mg three times daily) decreased the maximum concentration and AUC of quetiapine (300 mg twice daily) by 80% and 87%, respectively.<sup>4</sup> Two retrospective reviews of therapeutic drug monitoring data also describe several patients whose quetiapine serum concentration/dose ratio was substantially lower than mean values during treatment with strong CYP3A4 inducers (carbamazepine, phenobarbital).<sup>5,6</sup><br><br>The suspected primary mechanism of these interactions is induction of CYP3A4 mediated quetiapine metabolism by the interacting agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Seroquel (quetiapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, April 2013.</p>\n<p>2. Prescribing information. Seroquel XR (quetiapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, April 2013.</p>\n<p>3. Wong YW, Yeh C and Thyrum PT, “The Effects of Concomitant Phenytoin Administration on the Steady-State Pharmacokinetics of Quetiapine,” <i>J Clin Psychopharmacol</i>, 2001, 21(1):89-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11199955\">[PubMed 11199955]</a></p>\n<p>4. Grimm SW, Richtand NM, Winter HR, et al, “Effects of Cytochrome P450 3A Modulators Ketoconazole and Carbamazepine on Quetiapine Pharmacokinetics,” <i>Br J Clin Pharmacol</i>, 2006, 61(1):58-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16390352\">[PubMed 16390352]</a></p>\n<p>5. Hasselstrom J and Linnet K, “Quetiapine Serum Concentrations in Psychiatric Patients: The Influence of Comedication,” <i>Ther Drug Monit</i>, 2004, 26(5):486-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385830\">[PubMed 15385830]</a></p>\n<p>6. Bakken GV, Rudberg I, Molden E, et al, “Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-Desalkylquetiapine in Psychiatric Patients,” <i>Ther Drug Monit</i>, 2011, 33(2):222-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383647\">[PubMed 21383647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7515":"<p><b>Title</b> St John's Wort / QUEtiapine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> QUEtiapine may enhance the serotonergic effect of St John's Wort. This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of QUEtiapine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit during treatment with St. John's wort. The quetiapine dose should be reduced to the previous/regular dose within 7-14 days of discontinuation of St. John's wort. Monitor quetiapine response closely, as well as for evidence of serotonin toxicity (e.g., mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (e.g., hyperthermia, muscle rigidity, autonomic dysfunction).</p> \n<p><b>Discussion</b> In a clinical study summarized in quetiapine U.S. prescribing information, coadministraiton of phenytoin (100 mg 3 times daily) decreased the maximum concentration and AUC of quetiapine (250 mg 3 times daily) by 73% and 81%, respectively.<sup>1,2,3</sup> Similarly, in a study of 18 psychiatric patients, carbamazepine (200 mg three times daily) decreased the maximum concentration and AUC of quetiapine (300 mg twice daily) by 80% and 87%, respectively.<sup>4</sup> Two retrospective reviews of therapeutic drug monitoring data also describe several patients whose quetiapine serum concentration/dose ratio was substantially lower than mean values during treatment with strong CYP3A4 inducers (carbamazepine, phenobarbital).<sup>5,6</sup><br><br>The suspected primary mechanism of these interactions is induction of CYP3A4 mediated quetiapine metabolism by the interacting agents. Quetiapine prescribing information recommends specific dose adjustments be considered during concomitant treatment with potent CYP3A4 inducers, and cites St. John's wort as an example of such an agent.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Seroquel (quetiapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, April 2013.</p>\n<p>2. Prescribing information. Seroquel XR (quetiapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, April 2013.</p>\n<p>3. Wong YW, Yeh C and Thyrum PT, “The Effects of Concomitant Phenytoin Administration on the Steady-State Pharmacokinetics of Quetiapine,” <i>J Clin Psychopharmacol</i>, 2001, 21(1):89-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11199955\">[PubMed 11199955]</a></p>\n<p>4. Grimm SW, Richtand NM, Winter HR, et al, “Effects of Cytochrome P450 3A Modulators Ketoconazole and Carbamazepine on Quetiapine Pharmacokinetics,” <i>Br J Clin Pharmacol</i>, 2006, 61(1):58-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16390352\">[PubMed 16390352]</a></p>\n<p>5. Hasselstrom J and Linnet K, “Quetiapine Serum Concentrations in Psychiatric Patients: The Influence of Comedication,” <i>Ther Drug Monit</i>, 2004, 26(5):486-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385830\">[PubMed 15385830]</a></p>\n<p>6. Bakken GV, Rudberg I, Molden E, et al, “Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-Desalkylquetiapine in Psychiatric Patients,” <i>Ther Drug Monit</i>, 2011, 33(2):222-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383647\">[PubMed 21383647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7548":"<p><b>Title</b> ALPRAZolam / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of ALPRAZolam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the use of itraconazole and alprazolam in combination. Alprazolam U.S. prescribing information specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Alprazolam U.S. prescribing information lists its use in combination with itraconazole as contraindicated due to the potential for increased alprazolam exposure and enhanced or prolonged sedative effects.<sup>1</sup> In a published clinical study, coadministration of itraconazole (200 mg/day orally for 6 days) increased the AUC of alprazolam (0.8 mg single oral dose) by roughly 2.7 fold in healthy volunteers.<sup>1,2</sup> Itraconazole significantly enhanced alprazolam pharmacodynamic effects via several measures (patient reported sleepiness, digit symbol substitution test, several others).<br><br>The suspected primary mechanism of this interaction is itraconazole inhibition of CYP3A4 mediated alprazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xanax (alprazolam). New York, NY: Pfizer Inc, 8/2011.</p>\n<p>2. Yasui N, Kondo T, Otani K, et al, “Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Alprazolam,” <i>Psychopharmacology (Berl)</i>, 1998, 139(3):269-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9784084\">[PubMed 9784084]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7549":"<p><b>Title</b> ALPRAZolam / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of ALPRAZolam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the use of systemic ketoconazole and alprazolam in combination. Alprazolam U.S. prescribing information specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Alprazolam U.S. prescribing information lists its use in combination with ketoconazole as contraindicated due to the potential for increased alprazolam exposure and enhanced or prolonged sedative effects.<sup>1</sup> In a published clinical study, coadministration of ketoconazole (200 mg twice daily for 2 days) increased the AUC of alprazolam (1.0 mg single oral dose) by roughly 4 fold in healthy volunteers.<sup>1,2</sup> Ketoconazole significantly enhanced alprazolam pharmacodynamic effects via several measures (patient reported drowsiness, digit symbol substitution test, several others).<br><br>The suspected primary mechanism of this interaction is itraconazole inhibition of CYP3A4 mediated alprazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xanax (alprazolam). New York, NY: Pfizer Inc, 8/2011.</p>\n<p>2. Greenblatt DJ, Wright CE, von Moltke LL, et al, “Ketoconazole Inhibition of Triazolam and Alprazolam Clearance: Differential Kinetic and Dynamic Consequences,” <i>Clin Pharmacol Ther</i>, 1998, 64(3):237-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757147\">[PubMed 9757147]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7550":"<p><b>Title</b> Levonordefrin / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Levonordefrin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of levonordefrin during or within 2 weeks of treatment with a monoamine oxidase inhibitor whenever possible. If levonordefrin cannot be avoided during this period, monitor closely for enhanced or prolonged increases in blood pressure.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for levonordefrin states that coadministraiton within 2 weeks of a monoamine oxidase inhibitor should be avoided, due to the potential for severe, prolonged hypertension.<sup>1</sup> The exact mechanism of this interaction is not clear. In a study of greyhound dogs, pretreatment with phenelzine (5 mg/kg) had no impact on the levonordefrin blood pressure response.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Carbocaine with Neo-Cobefrin (mepivacaine and levonordefrin). Cambridge, ON: Novocol Pharmaceutical of Canada, Inc., 8/2009.</p>\n<p>2. Yagiela JA, Duffin SR and Hunt LM, “Drug Interactions and Vasoconstrictors used in local anesthetic solutions.” <i>Oral Surg Oral Med Oral Pathol</i>, 1985, 59(6):565-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3892411\">[PubMed 3892411]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7551":"<p><b>Title</b> Norepinephrine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Norepinephrine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Use norepinephrine with caution in patients receiving monoamine oxidase inhibitors, and monitor blood pressure response closely.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exception</b> Tedizolid</p>\n</div> \n<p><b>Discussion</b> Norepinephrine U.S. prescribing information recommends extreme caution when used concomitantly with a monoamine oxidase inhibitor (MAOI).<sup>1</sup> Published reports of the clinical effects of such combinations are conflicting. A small clinical study in 4 healthy volunteers noted no substantial modification of norepinephrine blood pressure effects following 8 days of treatment with phenelzine (45 mg/day).<sup>2</sup> Other human studies have detected no or minimal impact of MAO inhibition on norepinephrine systemic effects.<sup>3,4,5,6</sup> In contrast, in a study of 3 healthy volunteers, heart rate effects of norepinephrine were enhanced in all subjects (1.6-4.3 fold) and blood pressure effects were enhanced in 2 of 3 subjects (1.3-2.7 fold) following 8-14 days of tranylcypromine (30 mg/day).<sup>7</sup> In another clinical study of 6 healthy volunteers, blood pressure responses to norepinephrine were greater in 4 of 6 subjects following tranylcypromine pretreatment.<sup>8</sup> <br><br>In contrast to other MAOIs, methylene blue has consistently enhanced blood pressure responses to norepinephrine or epinephrine, and/or decreased dose requirements of these drugs.<sup>9,10,11,12</sup> <br><br>MAOIs could theoretically inhibit the systemic clearance of norepinephrine via inhibition of its MAO-dependent degradation. However, based on the preponderance of clinical data, these effects are likely minor in most patients. The more consistent effects seen with methylene blue likely relate more to its inhibitory effects on inducible nitric oxide synthases and guanylate cyclase, and/or effects on other non-MAO systems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Levophed (norepinephrine). Lake Forest, IL: Hospira, Inc., November 2009.</p>\n<p>2. Elis J, Laurence DR, Mattie H, et al, “Modification by Monoamine Oxidase Inhibitors of the Effect of Some Sympathomimetics on Blood Pressure,” <i>Br Med J</i>, 1967, 2(5544):75-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6020852\">[PubMed 6020852]</a></p>\n<p>3. Horowitz D, Goldberg LI and Sjoerdsma A, “Increased Blood Pressure Responses to Dopamine and Norepinephrine Produced by Monoamine Oxidase Inhibitors in Man,” <i>J Lab Clin Med</i>, 1960, 56:747-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13716048\">[PubMed 13716048]</a></p>\n<p>4. Barar FS, Boakes AJ, Benedikter LB, et al, “Interactions Between Catecholamines and Tricyclic and Monoamine Oxidase Inhibitor Antidepressive Agents in Man,” <i>Br J Pharmacol</i>, 1971, 43(2):472P-473P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158242\">[PubMed 5158242]</a></p>\n<p>5. Boakes AJ, Laurence DR, Teoh PC, et al, “Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,” <i>Br Med J</i>, 1973, 1(5849):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>6. Cusson JR, Goldenberg E and Larochelle P, “Effect of a Novel Monoamine-Oxidase Inhibitor, Moclobemide on the Sensitivity to Intravenous Tyramine and Norepinephrine in Humans,” <i>J Clin Pharmacol</i>, 1991, 31(5):462-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2050833\">[PubMed 2050833]</a></p>\n<p>7. Cuthbert MF and Vere DW, “Potentiation of the Cardiovascular Effects of Some Catecholamines by a Monoamine Oxidase Inhibitor,” <i> Br J Pharmacol</i>, 1971, 43(2):471P-472P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158241\">[PubMed 5158241]</a></p>\n<p>8. Bieck PR and Antonin KH, “Monoamine Oxidase Inhibition by Tranylcypromine: Assessment in Human Volunteers,” <i>Eur J Clin Pharmacol</i>, 1982, 22(4):301-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7106165\">[PubMed 7106165]</a></p>\n<p>9. Kirov MY, Evgenov OV, Evgenov NV, et al, “Infusion of Methylene Blue in Human Septic Shock: A Pilot, Randomized, Controlled Study,” <i>Crit Care Med</i>, 2001, 29(10):1860-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11588440\">[PubMed 11588440]</a></p>\n<p>10. Koelzow H, Gedney JA, Baumann J, et al, “The Effect of Methylene Blue on the Hemodynamic Changes During Ischemia Reperfusion Injury in Orthotopic Liver Rransplantation,” <i>Anesth Analg</i>, 2002, 94(4):824-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11916779\">[PubMed 11916779]</a></p>\n<p>11. Maslow AD, Stearns G, Butala P, et al, “The Hemodynamic Effects of Methylene Blue When Administered at the Onset of Cardiopulmonary Bypass,” <i>Anesth Analg</i>, 2006, 103(1):2-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16790616\">[PubMed 16790616]</a></p>\n<p>12. van Haren FM, Pickkers P, Foudraine N, et al, “The Effects of Methylene Blue Infusion on Gastric Tonometry and Intestinal Fatty Acid Binding Protein Levels in Septic Shock Patients,” <i>J Crit Care</i>, 2010, 25(2):358.e1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20381302\">[PubMed 20381302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7553":"<p><b>Title</b> Epinephrine (Racemic) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Epinephrine (Racemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Use epinephrine with caution in patients receiving monoamine oxidase inhibitors, and monitor blood pressure response closely.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exception</b> Tedizolid</p>\n</div> \n<p><b>Discussion</b> Epinephrine U.S. and Canadian product labeling warns that coadministration with monoamine oxidase inhibitors (MAOIs) may potentiate the effects of epinephrine.<sup>1,2</sup> In a study of 3 healthy volunteers, epinephrine induced increases in heart rate and systolic blood pressure were enhanced (by 1.8-4.5 fold and 1.8-3 fold, respectively) in all subjects following 8-14 days of tranylcypromine (30 mg/day).<sup>3</sup> In contrast, several reports describe a lack of clinical impact of treatment with MAOIs on blood pressure effects of epinephrine (including, in one case report, ophthalmic epinephrine).<sup>4,5,6</sup><br><br>In contrast to other MAOIs, methylene blue has consistently enhanced blood pressure responses to norepinephrine or epinephrine, and/or decreased dose requirements of these drugs, in clinical studies.<sup>7,8,9,10</sup> <br><br>MAOIs could theoretically inhibit the systemic clearance of epinephrine via inhibition of its MAO-dependent degradation. However, based on the preponderance of clinical data, these effects are likely minor in most patients. The more consistent effects seen with methylene blue likely relate more to its inhibitory effects on inducible nitric oxide synthases and guanylate cyclase, and/or effects on other non-MAO systems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. EpiPen (epinephrine). Napa, CA: Mylan Specialty L.P., 8/2012. </p>\n<p>2. Product monograph. EpiPen (epinephrine). Napa, CA: Dey Pharma, L.P., March 2012. </p>\n<p>3. Cuthbert MF and Vere DW, “Potentiation of the Cardiovascular Effects of Some Catecholamines by a Monoamine Oxidase Inhibitor,” <i> Br J Pharmacol</i>, 1971, 43(2):471P-472P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158241\">[PubMed 5158241]</a></p>\n<p>4. Barar FS, Boakes AJ, Benedikter LB, et al, “Interactions Between Catecholamines and Tricyclic and Monoamine Oxidase Inhibitor Antidepressive Agents in Man,” <i>Br J Pharmacol</i>, 1971, 43(2):472P-473P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158242\">[PubMed 5158242]</a></p>\n<p>5. Boakes AJ, Laurence DR, Teoh PC, et al, “Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,” <i>Br Med J</i>, 1973, 1(5849):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>6. Thompson DS, Sweet RA, Marzula K, et al, “Lack of Interaction of Monoamine Oxidase Inhibitors and Epinephrine in an Older Patient,” <i>J Clin Psychopharmacol</i>, 1997, 17(4):322-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241014\">[PubMed 9241014]</a></p>\n<p>7. Kirov MY, Evgenov OV, Evgenov NV, et al, “Infusion of Methylene Blue in Human Septic Shock: A Pilot, Randomized, Controlled Study,” <i>Crit Care Med</i>, 2001, 29(10):1860-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11588440\">[PubMed 11588440]</a></p>\n<p>8. Koelzow H, Gedney JA, Baumann J, et al, “The Effect of Methylene Blue on the Hemodynamic Changes During Ischemia Reperfusion Injury in Orthotopic Liver Rransplantation,” <i>Anesth Analg</i>, 2002, 94(4):824-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11916779\">[PubMed 11916779]</a></p>\n<p>9. Maslow AD, Stearns G, Butala P, et al, “The Hemodynamic Effects of Methylene Blue When Administered at the Onset of Cardiopulmonary Bypass,” <i>Anesth Analg</i>, 2006, 103(1):2-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16790616\">[PubMed 16790616]</a></p>\n<p>10. van Haren FM, Pickkers P, Foudraine N, et al, “The Effects of Methylene Blue Infusion on Gastric Tonometry and Intestinal Fatty Acid Binding Protein Levels in Septic Shock Patients,” <i>J Crit Care</i>, 2010, 25(2):358.e1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20381302\">[PubMed 20381302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7554":"<p><b>Title</b> EPINEPHrine (Nasal) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Nasal). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Use epinephrine with caution in patients receiving monoamine oxidase inhibitors, and monitor blood pressure response closely.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exception</b> Tedizolid</p>\n</div> \n<p><b>Discussion</b> Epinephrine U.S. and Canadian product labeling warns that coadministration with monoamine oxidase inhibitors (MAOIs) may potentiate the effects of epinephrine.<sup>1,2</sup> In a study of 3 healthy volunteers, epinephrine induced increases in heart rate and systolic blood pressure were enhanced (by 1.8-4.5 fold and 1.8-3 fold, respectively) in all subjects following 8-14 days of tranylcypromine (30 mg/day).<sup>3</sup> In contrast, several reports describe a lack of clinical impact of treatment with MAOIs on blood pressure effects of epinephrine (including, in one case report, ophthalmic epinephrine).<sup>4,5,6</sup><br><br>In contrast to other MAOIs, methylene blue has consistently enhanced blood pressure responses to norepinephrine or epinephrine, and/or decreased dose requirements of these drugs, in clinical studies.<sup>7,8,9,10</sup> <br><br>MAOIs could theoretically inhibit the systemic clearance of epinephrine via inhibition of its MAO-dependent degradation. However, based on the preponderance of clinical data, these effects are likely minor in most patients. The more consistent effects seen with methylene blue likely relate more to its inhibitory effects on inducible nitric oxide synthases and guanylate cyclase, and/or effects on other non-MAO systems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. EpiPen (epinephrine). Napa, CA: Mylan Specialty L.P., 8/2012. </p>\n<p>2. Product monograph. EpiPen (epinephrine). Napa, CA: Dey Pharma, L.P., March 2012. </p>\n<p>3. Cuthbert MF and Vere DW, “Potentiation of the Cardiovascular Effects of Some Catecholamines by a Monoamine Oxidase Inhibitor,” <i> Br J Pharmacol</i>, 1971, 43(2):471P-472P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158241\">[PubMed 5158241]</a></p>\n<p>4. Barar FS, Boakes AJ, Benedikter LB, et al, “Interactions Between Catecholamines and Tricyclic and Monoamine Oxidase Inhibitor Antidepressive Agents in Man,” <i>Br J Pharmacol</i>, 1971, 43(2):472P-473P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158242\">[PubMed 5158242]</a></p>\n<p>5. Boakes AJ, Laurence DR, Teoh PC, et al, “Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,” <i>Br Med J</i>, 1973, 1(5849):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>6. Thompson DS, Sweet RA, Marzula K, et al, “Lack of Interaction of Monoamine Oxidase Inhibitors and Epinephrine in an Older Patient,” <i>J Clin Psychopharmacol</i>, 1997, 17(4):322-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241014\">[PubMed 9241014]</a></p>\n<p>7. Kirov MY, Evgenov OV, Evgenov NV, et al, “Infusion of Methylene Blue in Human Septic Shock: A Pilot, Randomized, Controlled Study,” <i>Crit Care Med</i>, 2001, 29(10):1860-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11588440\">[PubMed 11588440]</a></p>\n<p>8. Koelzow H, Gedney JA, Baumann J, et al, “The Effect of Methylene Blue on the Hemodynamic Changes During Ischemia Reperfusion Injury in Orthotopic Liver Rransplantation,” <i>Anesth Analg</i>, 2002, 94(4):824-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11916779\">[PubMed 11916779]</a></p>\n<p>9. Maslow AD, Stearns G, Butala P, et al, “The Hemodynamic Effects of Methylene Blue When Administered at the Onset of Cardiopulmonary Bypass,” <i>Anesth Analg</i>, 2006, 103(1):2-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16790616\">[PubMed 16790616]</a></p>\n<p>10. van Haren FM, Pickkers P, Foudraine N, et al, “The Effects of Methylene Blue Infusion on Gastric Tonometry and Intestinal Fatty Acid Binding Protein Levels in Septic Shock Patients,” <i>J Crit Care</i>, 2010, 25(2):358.e1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20381302\">[PubMed 20381302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7555":"<p><b>Title</b> Artemether / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the concomitant use of artemether with any strong CYP3A4 inducer. This is considered contraindicated per artemether/lumefantrine U.S. prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Artemether/lumefantrine U.S. prescribing information states that coadministration with any strong CYP3A4 inducer is contraindicated, due to the potential for loss of antimalarial response associated with decreased exposure to artemether and lumefantrine.<sup>1</sup> In clinical studies, artemether and dihydroartemisinin AUCs were lower during concomitant use of rifampin (89% and 85%, respectively), etravirine (51-79% and 46-78%, respectively), and nevirapine (72% and 38%, respectively, per one study; artemether + dihydroartemisinin AUC 24% lower per another).<sup>1,2,3,4</sup> The suspected primary mechanism of these interactions is induction of the CYP3A4 mediated metabolism of artemether by the coadministered drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Coartem (artemether and lumefantrine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 4/2013.</p>\n<p>2. Huang L, Parikh S, Rosenthal PJ, et al, “Concomitant Efavirenz Reduces Pharmacokinetic Exposure to the Antimalarial Drug Artemether-Lumefantrine in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2012, 61(3):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22918158\">[PubMed 22918158]</a></p>\n<p>3. Byakika-Kibwika P, Lamorde M, Mayito J, et al, “Significant Pharmacokinetic Interactions Between Artemether/Lumefantrine and Efavirenz or Nevirapine in HIV-Infected Ugandan Adults,” <i>J Antimicrob Chemother</i>, 2012, 67(9):2213-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22687893\">[PubMed 22687893]</a></p>\n<p>4. Kredo T, Mauff K, Van der Walt JS, et al, “Interaction Between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients,” <i>Antimicrob Agents Chemother</i>, 2011, 55(12):5616-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21947399\">[PubMed 21947399]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7556":"<p><b>Title</b> Artemether / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. St John's Wort may decrease the serum concentration of Artemether. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of artemether with St. John's wort. This combination is considered contraindicated per artemether/lumefantrine U.S. prescribing information.</p> \n<p><b>Discussion</b> Artemether/lumefantrine U.S. prescribing information states that coadministration with any strong CYP3A4 inducer is contraindicated (specifically citing St. John's wort as an example of such an agent), due to the potential for loss of antimalarial response associated with decreased exposure to artemether and lumefantrine.<sup>1</sup> In clinical studies, artemether and dihydroartemisinin AUCs were lower during concomitant use of rifampin (89% and 85%, respectively), etravirine (51-79% and 46-78%, respectively), and nevirapine (72% and 38%, respectively, per one study; artemether + dihydroartemisinin AUC 24% lower per another).<sup>1,2,3,4</sup> The suspected primary mechanism of these interactions is induction of the CYP3A4 mediated metabolism of artemether by the coadministered drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Coartem (artemether and lumefantrine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 4/2013.</p>\n<p>2. Huang L, Parikh S, Rosenthal PJ, et al, “Concomitant Efavirenz Reduces Pharmacokinetic Exposure to the Antimalarial Drug Artemether-Lumefantrine in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2012, 61(3):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22918158\">[PubMed 22918158]</a></p>\n<p>3. Byakika-Kibwika P, Lamorde M, Mayito J, et al, “Significant Pharmacokinetic Interactions Between Artemether/Lumefantrine and Efavirenz or Nevirapine in HIV-Infected Ugandan Adults,” <i>J Antimicrob Chemother</i>, 2012, 67(9):2213-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22687893\">[PubMed 22687893]</a></p>\n<p>4. Kredo T, Mauff K, Van der Walt JS, et al, “Interaction Between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients,” <i>Antimicrob Agents Chemother</i>, 2011, 55(12):5616-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21947399\">[PubMed 21947399]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7557":"<p><b>Title</b> Lumefantrine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the concomitant use of lumefantrine with any strong CYP3A4 inducer. This is considered contraindicated per artemether/lumefantrine U.S. prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Artemether/lumefantrine U.S. prescribing information states that coadministration with any strong CYP3A4 inducer is contraindicated, due to the potential for loss of antimalarial response associated with decreased exposure to artemether and lumefantrine.<sup>1</sup> In clinical studies, lumefantrine exposure was lower during concomitant use of rifampin (AUC 68% lower), etravirine (day 7 concentration 46% lower), and nevirapine (maximum concentration, AUC, and day 7 concentration 28%, 56%, and 30% lower, respectively).<sup>1,2,3,4</sup> The suspected primary mechanism of these interactions is induction of the CYP3A4 mediated metabolism of lumefantrine by the coadministered drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Coartem (artemether and lumefantrine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 4/2013.</p>\n<p>2. Huang L, Parikh S, Rosenthal PJ, et al, “Concomitant Efavirenz Reduces Pharmacokinetic Exposure to the Antimalarial Drug Artemether-Lumefantrine in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2012, 61(3):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22918158\">[PubMed 22918158]</a></p>\n<p>3. Byakika-Kibwika P, Lamorde M, Mayito J, et al, “Significant Pharmacokinetic Interactions Between Artemether/Lumefantrine and Efavirenz or Nevirapine in HIV-Infected Ugandan Adults,” <i>J Antimicrob Chemother</i>, 2012, 67(9):2213-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22687893\">[PubMed 22687893]</a></p>\n<p>4. Kredo T, Mauff K, Van der Walt JS, et al, “Interaction Between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients,” <i>Antimicrob Agents Chemother</i>, 2011, 55(12):5616-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21947399\">[PubMed 21947399]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7558":"<p><b>Title</b> Lumefantrine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Lumefantrine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of lumefantrine with St. John's wort. This combination is considered contraindicated per artemether/lumefantrine U.S. prescribing information.</p> \n<p><b>Discussion</b> Artemether/lumefantrine U.S. prescribing information states that coadministration with any strong CYP3A4 inducer is contraindicated (specifically citing St. John's wort as an example of such an agent), due to the potential for loss of antimalarial response associated with decreased exposure to artemether and lumefantrine.<sup>1</sup> In clinical studies, lumefantrine exposure was lower during concomitant use of rifampin (AUC 68% lower), etravirine (day 7 concentration 46% lower), and nevirapine (maximum concentration, AUC, and day 7 concentration 28%, 56%, and 30% lower, respectively).<sup>1,2,3,4</sup> The suspected primary mechanism of these interactions is induction of the CYP3A4 mediated metabolism of lumefantrine by the coadministered drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Coartem (artemether and lumefantrine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 4/2013.</p>\n<p>2. Huang L, Parikh S, Rosenthal PJ, et al, “Concomitant Efavirenz Reduces Pharmacokinetic Exposure to the Antimalarial Drug Artemether-Lumefantrine in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2012, 61(3):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22918158\">[PubMed 22918158]</a></p>\n<p>3. Byakika-Kibwika P, Lamorde M, Mayito J, et al, “Significant Pharmacokinetic Interactions Between Artemether/Lumefantrine and Efavirenz or Nevirapine in HIV-Infected Ugandan Adults,” <i>J Antimicrob Chemother</i>, 2012, 67(9):2213-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22687893\">[PubMed 22687893]</a></p>\n<p>4. Kredo T, Mauff K, Van der Walt JS, et al, “Interaction Between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients,” <i>Antimicrob Agents Chemother</i>, 2011, 55(12):5616-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21947399\">[PubMed 21947399]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7559":"<p><b>Title</b> Doxycycline / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Doxycycline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for reduced doxycycline response in patients receiving rifampin, particularly when these drugs are not being used as part of the same established anti-infective protocol.</p> \n<p><b>Discussion</b> In a clinical study of 19 patients with brucellosis, doxycycline (100 mg orally twice daily) AUC was 58% lower in patients treated concomitantly with rifampin (600-1,200 mg/day, depending on patient weight).<sup>1</sup> The suspected mechanism of interaction between these agents is rifampin induction of doxycycline metabolism and/or excretion, although the specific pathway(s) affected is/are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Colmenero JD, Fernandez-Gallardo LC, Agundez JA, et al, “Possible Implications of Doxycycline-Rifampin Interaction for Treatment of Brucellosis,” <i>Antimicrob Agents Chemother</i>, 1994, 38(12):2798-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7695265\">[PubMed 7695265]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7561":"<p><b>Title</b> Alendronate / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may increase the serum concentration of Alendronate. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> The alendronate bioavailability was doubled when oral alendronate was given to postmenopausal women receiving intravenous (IV) ranitidine.<sup>1</sup> The clinical significance of this change is uncertain.<sup>2,3</sup><br><br>It is not clear whether this interaction is pH-related, as the more potent pH-increasing proton pump inhibitors have been shown to have a negative or neutral effect on bisphosphonate effectiveness,<sup>4,5,6,7,8,9</sup> with no available data confirming or refuting a pH-related pharmacokinetic interaction. Also, it is unclear whether this interaction is specific to ranitidine and/or to the IV route of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gertz BJ, Holland SD, Kline WF, et al, “Studies of the Oral Bioavailability of Alendronate,” <i>Clin Pharmacol Ther</i>, 1995, 58(3):288-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7554702\">[PubMed 7554702]</a></p>\n<p>2. Prescribing information. Fosamax (alendronate). Whitehouse Station, NJ: Merck &amp; Co., Inc., 04/2013.</p>\n<p>3. Prescribing information. Binosto (alendronate). San Antonio, TX: Mission Pharmacal, 4/2013.</p>\n<p>4. Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” <i>Arch Intern Med</i>, 2011, 171(11):998-1004. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21321287\">[PubMed 21321287]</a></p>\n<p>5. Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” <i>Endokrynol Pol</i>, 2011, 62(1):84-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21365585\">[PubMed 21365585]</a></p>\n<p>6. Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” <i>Bone</i>, 2010, 47(2):169-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20493982\">[PubMed 20493982]</a></p>\n<p>7. Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” <i>Drug Saf</i>, 2009, 32(9):775-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19670917\">[PubMed 19670917]</a></p>\n<p>8. de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” <i>Osteoporos Int</i>, 2009, 20(12):1989-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19333676\">[PubMed 19333676]</a></p>\n<p>9. Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” <i>Osteoporos Int</i>, 2012, 23(1):277-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21365461\">[PubMed 21365461]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7562":"<p><b>Title</b> Methylphenidate / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This interaction is of even greater significance for patients using the Ritalin LA or Metadate CD brands of methylphenidate.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients should avoid alcohol consumption while taking methylphenidate. This is advisable for all patients taking any methylphenidate product, but this is even more important for patients taking the Metadate CD, Ritalin LA, or Quillichew ER brands of extended-release methylphenidate, as concurrent alcohol may substantially increase the rate of drug release and absorption from these products.</p> \n<p><b>Discussion</b> The average AUC of active d-methylphenidate was 21-25% higher when racemic methylphenidate was given within 30 minutes (before or after) of alcohol in studies of healthy volunteers (n=20-24).<sup>1,2</sup> Alcohol also appeared to particularly increase d-methylphenidate concentrations during the absorption phase, as well as increasing the subjective effects of methylphenidate.<sup>2</sup><br><br>The mechanism for this specific interaction is thought to be decreased esterase metabolism of methylphenidate via ethanol and/or ethylphenidate (transesterification product of ethanol and methylphenidate).<sup>1,2</sup><br><br>An additional interaction concern is that alcohol (40% concentration) has been shown to alter the release characteristics of some extended-release methylphenidate products (Ritalin LA, Metadate CD, and Quillichew ER), resulting in a release of 84-98% of the total methylphenidate within the first 30 to 60 minutes.<sup>3,4,5</sup> This does not appear to apply to all extended-release products, as a similar study of alcohol (40%) with the Concerta brand of extended-release methylphenidate was not associated with any significant change in methylphenidate release within the first hour.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Patrick KS, Straughn AB, Minhinnett RR, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. <i>Clin Pharmacol Ther</i>. 2007;81(3):346-353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17339864\">[PubMed 17339864]</a></p>\n<p>2. Patrick KS, Straughn AB, Reeves OT 3rd, et al. Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. <i>Drug Metab Dispos</i>. 2013;41(1):197-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23104969\">[PubMed 23104969]</a></p>\n<p>3. Metadate CD (methylphenidate) [prescribing information]. Smyrna, GA: UCB Inc; 2013.</p>\n<p>4. Ritalin LA (methylphenidate) [prescribing information]. East Hanover, NJ: Novartis AG; April 2015.</p>\n<p>5. Quillichew ER (methylphenidate) [prescribing information]. New York, NY: Pfizer Inc; December 2015.</p>\n<p>6. Concerta (methylphenidate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7563":"<p><b>Title</b> Teicoplanin / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): An interaction between these agents is only anticipated with oral teicoplanin administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may diminish the therapeutic effect of Teicoplanin. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider separating doses of oral teicoplanin and bile acid sequestrants by several hours.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n</div> \n<p><b>Discussion</b> In one in vitro study, coincubation of teicoplanin (2 mg/mL) with cholestyramine (12 mg/mL) reduced its activity against <i>Bacillus subtilis</i> in an agar diffusion test by over 99%.<sup>1</sup> The suspected mechanism of this interaction is cholestyramine binding to teicoplanin. Caution may be warranted if these agents are coadministered orally. No clinical data characterizing the impact of any binding in vivo are presently available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pantosti A, Luzzi I, Cardines R, et al, “Comparison of the In Vitro Activities of Teicoplanin and Vancomycin Against Clostridium difficile and Their Interactions With Cholestyramine,” <i>Antimicrob Agents Chemother</i>, 1985, 28(6):847-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2935077\">[PubMed 2935077]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7564":"<p><b>Title</b> Flucloxacillin / Piperacillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Piperacillin may increase the serum concentration of Flucloxacillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for enhanced systemic effects (including toxic effects) of flucloxacillin if coadministered with piperacillin.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, the simultaneous intravenous coadministration of piperacillin (1.5 g) with flucloxacillin (0.5 g) increased the flucloxacillin AUC by 69%.<sup>1</sup> In the same study, the simultaneous intravenous coadministration of piperacillin (3 g) with flucloxacillin (1 g) increased the flucloxacillin AUC by 113%.<sup>1</sup> In the higher dose study, piperacillin nonrenal clearance decreased by 17% and the fraction excreted in urine increased 7%; piperacillin pharmacokinetic variables were otherwise unaffected by flucloxacillin coadministration.<br><br>The exact mechanisms of this interaction are unclear. Piperacillin may decrease the renal clearance of flucloxacillin via competition for renal tubular transport.<sup>1</sup> However, nonrenal clearance was also decreased in the studies above, by an unknown mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Sorgel F. Inhibition of flucloxacillin tubular renal secretion by piperacillin. <i>Br J Clin Pharmacol</i>. 2008;66(5):648-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19032173\">[PubMed 19032173]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7565":"<p><b>Title</b> Vitamin K Antagonists / Flucloxacillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Flucloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. Flucloxacillin may decrease the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Monitor INR closely during concomitant treatment with flucloxacillin and a vitamin K antagonist.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Three published case reports describe warfarin-treated patients who had apparent decreased warfarin effects and/or increased warfarin dose requirements during treatment with flucloxacillin.<sup>1,2,3</sup> In one of these cases, a subtherapeutic INR was associated with development of ischemic stroke.<sup>1</sup><br><br>The specific mechanism of this potential interaction is not certain, but one possible mechanism is induction of CYP3A4-mediated metabolism of (R)-warfarin by flucloxacillin, leading to lower warfarin concentrations and effects.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Merwick A, Hannon N, Kelly PJ, O'Rourke K. Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke. <i>Eur J Clin Pharmacol</i>. 2010;66(6):643-644. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20204336\">[PubMed 20204336]</a></p>\n<p>2. Garg A, Mohammed M. Decreased INR response secondary to warfarin-flucloxacillin interaction. <i>Ann Pharmacother</i>. 2009;43(7):1374-1375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19584391\">[PubMed 19584391]</a></p>\n<p>3. Choi PY, Phillips KL, Rae I. High-dose intravenous flucloxacillin may affect warfarin therapy. <i>Med J Aust</i>. 2011;194(11):613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21644882\">[PubMed 21644882]</a></p>\n<p>4. Huwyler J, Wright MB, Gutmann H, Drewe J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. <i>Curr Drug Metab</i>. 2006;7(2):119-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16472102\">[PubMed 16472102]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7566":"<p><b>Title</b> QuiNIDine / Flucloxacillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Flucloxacillin may decrease the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for decreased quinidine serum concentrations during treatment with flucloxacillin.</p> \n<p><b>Discussion</b> A published case report describes a 63-year-old female patient whose quinidine plasma concentrations remained below the target therapeutic range despite several dose increases (to a maximum of 2800 mg/day) during treatment with flucloxacillin.<sup>1</sup> The plasma quinidine concentration later rose into the target therapeutic range on a substantially reduced quinidine dose (600 mg three times daily). <br><br>The mechanism by which flucloxacillin may decrease quinidine serum concentrations or increase quinidine dose requirements is unknown. Some in vitro data support a potential for flucloxacillin to induce expression of CYP3A4 and P-glycoprotein,<sup>2</sup> either of which could theoretically contribute to these effects, although the significance of any induction in humans has no substantial additional support.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Comuth WJ, Comuth JA, Hauer RN, Malingre MM. Interaction of flucloxacillin and quinidine. <i>Eur J Clin Pharmacol</i>. 2012;68(5):891-893. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22203424\">[PubMed 22203424]</a></p>\n<p>2. Huwyler J, Wright MB, Gutmann H, Drewe J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. <i>Curr Drug Metab</i>. 2006;7(2):119-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16472102\">[PubMed 16472102]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}